Furthermore,
Biotech abivax flies over 385%:
The leap in its course comes after the announcement of positive results of two advanced. Moreover, clinical trials in chronic intestine disease.
Abivax flies away. Furthermore, The action of the biotechnology company specializing in the development of treatment for chronic inflammatory diseases. Moreover, leaping more than 380% on Wednesday morning on the Paris Stock Exchange after the announcement of positive results of two advanced clinical trials in a chronic intestine disease. Consequently, After being suspended about two hours since the opening, the action was flying from 383.10% to 43 euros at 11:18 am on the Paris Stock Exchange, in a market up 1.54%. Furthermore, The evaluation of the experimental medication Obefazimod. in rectocolitis moderate to severe hemorrhagic, showed a “remission” Symptoms of the disease, according to a statement from Abivax, listed in Paris and biotech abivax flies over 385% New York. Rectocolite hemorrhagic (RCH), frequent in industrialized countries, is most often diagnosed in young subjects, aged 20 to 30, according to health insurance.
In France, it affects almost a person in 1,000, with each year 5 new cases per 100,000 inhabitants. The clinical trials conducted simultaneously, included 1,175 patients from more than 600 clinical trial centers distributed in 36 countries. They have “Demonstrated that Obefazimod met the main evaluation criterion of the American Medicines Agency (FDA). namely clinical remission at week 8” For the 50 mg dosage once a day, according to Abivax. Patients, who had not adequately responded to other therapies, received either Obefazimod or a placebo for 8 weeks. “The solidity of these results reinforces our conviction in the potential of Obefazimod (…) to become a new transformative therapeutic option for patients suffering from RCH”said the managing director. Marc de Garidel, in the press release.
Pass biotech abivax flies over 385% advertising
New fundraising – Biotech abivax flies over 385%
Obefazimod’s safety profile has remained consistent with previous clinical data, according to Abivax. This oral tablet “Stimulates a natural brake on inflammation. the MIR-124, and therefore acts on the different ways of inflammation, which explains the sustainable action of this medication”underlined Doctor Philippe Pouletty, founder of Abivax and managing director of Truffle Capital, a fund that creates and supports biotechs. “With nearly 1. 300 treated patients, it is one of the biggest clinical trials carried out in the world for rectocolitis hemorrhagic”added Philippe Pouletty, who founded and chaired for 10 years the company created in 2013.
To verify the efficiency. tolerance of treatment over a longer duration, a so -called study of «maintenance» Over 44 weeks is underway and its main results are expected in the second quarter of 2026. Subject to positive results of this study. Abivax plans to submit a request biotech abivax flies over 385% for authorization to marry American and European market «Au Second semester 2026». Abivax raised $ 500 million in 2023, more than 230 million, including its IPO on the NASDAQ.
Further reading: The point on two major competitions – the new platform – French justice authorizes its parole – rise in net profit over one year – Samy Bedja will sign for 3 years – What is season 2 worth? The opinion of criticisms.
